Switch Subset

Observed efficacy in switch subset at ≥96 weeks1,2

DESCOVY FOR PrEP® was noninferior to FTC/TDF

DESCOVY® (n=459)

100%

OF PATIENTS WHO SWITCHED

FTC/TDF (n=438)

99.8%

OF PATIENTS WHO CONTINUED

REMAINED HIV NEGATIVE

AT PRIMARY ANALYSIS AND ≥96 WEEKS


  • Patients who switched: Patients who were using FTC/TDF at baseline and randomized to DESCOVY FOR PrEP
  • Patients who continued: Patients using FTC/TDF at baseline who were randomized to continue using FTC/TDF
RENAL DATA

FTC/TDF=emtricitabine/tenofovir disoproxil fumarate.